PremiumThe FlyTeva, Alvotech announce FDA approval of interchangeability for SELARSDI Teva price target lowered to $20 from $24 at HSBC Teva Pharmaceutical’s Strategic Focus on EBITDA Growth and Cost Efficiencies Drives Buy Rating PremiumThe FlyTeva announces FDA acceptance of sBLA for AJOVY Positive Outlook for Teva Pharmaceuticals: Buy Rating Reiterated Amid Growth Initiatives and Improved Transparency Teva announces presentation of survey study on TEV-‘749 PremiumRatingsTeva Pharmaceutical’s Promising TL1a Program Drives Buy Rating Amid Strong Phase 2 Data for Duvakitug Teva holds a pharmaceutical update conference call Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study 
